ID6610 Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901)

Status:

Topic selection

Technology type:

Medicine

Decision:

Awaiting decision

Provisional Schedule

Invitation to participate:

30 September 2025

For further information on how we select topics for development, please see our page about prioritising our guidance topics